SP-333: Phase I started

Synergy began a single-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending-doses of 0.1, 0.3, 1, 3, 10, 30 and 60 mg oral SP-333 in about 56 healthy volunteers. Synergy said a m...